Zhejiang Betapharma

China

Zhejiang Betapharma

China
SEARCH FILTERS
Time filter
Source Type

Hu S.,Zhejiang Betapharma | Xie G.,Betapharma United States | Zhang D.X.,Betapharma United States | Davis C.,Betapharma United States | And 7 more authors.
Bioorganic and Medicinal Chemistry Letters | Year: 2012

Crown ether fused anilinoquinazoline analogues were synthesized as novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Representative compounds showed potent and selective EGFR inhibitory activities in an in vitro EGFR kinase assay and an EGFR-mediated intracellular tyrosine phosphorylation assay. The synthesis and preliminary biological, physical, and pharmacokinetic evaluation of these fused quinazoline compounds is reported. © 2012 Elsevier Ltd. All rights reserved.


PubMed | Zhejiang Betapharma
Type: Journal Article | Journal: Bioorganic & medicinal chemistry letters | Year: 2012

Crown ether fused anilinoquinazoline analogues were synthesized as novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Representative compounds showed potent and selective EGFR inhibitory activities in an in vitro EGFR kinase assay and an EGFR-mediated intracellular tyrosine phosphorylation assay. The synthesis and preliminary biological, physical, and pharmacokinetic evaluation of these fused quinazoline compounds is reported.

Loading Zhejiang Betapharma collaborators
Loading Zhejiang Betapharma collaborators